Kevin McRaith, CEO, is guiding the WellDoc team in the successful launch and continued development of the BlueStar Mobile Prescription Therapy. Under his leadership, the WellDoc team has engineered an innovative commercial approach to BlueStar's positioning in the marketplace, and achieved success in the initial targeted launch of BlueStar.

As CEO, Kevin is responsible for the sales, marketing, development and technical teams. His results-driven management team is focused on the successful delivery of technical patient solutions and product training.

Prior to joining WellDoc, Kevin served as Vice President of Sales and Marketing at Human Genome Sciences. In his leadership role with Human Genome Sciences, Kevin hired and led the commercial organization responsible for the successful launch of Benlysta®. During his time in this position, Kevin also chaired the Joint Development Committee, Joint Commercial Committee and the Joint Steering Committee with GlaxoSmithKline.

Kevin also served as Vice President of Sales and Marketing at Hematology Franchise at Genentech where he led the team through the strategic development and sales and marketing execution for Rituxan®. He also managed the pipeline of hematology products.

Prior to his tenure at Genentech, Kevin served in numerous sales and marketing roles of increasing responsibility over 14 years at Abbott Laboratories where he worked on key product launches, including Depakote®, Biaxin®, Kaletra®, Micardis® and Tricor®. His last role at Abbott was General Manager of the Anti-Infective franchise. Prior to Abbott, Kevin started his career at Baxter Healthcare, where he held various roles in sales and marketing.